Treatment
Somatostatin clinical trials
We’re tracking 31 recruiting studies that include Somatostatin, each written for real people, not researchers, below.
Recruiting studies
- NCT06345079RecruitingPhase 2
Stopping Somatostatin Analogues After PRRT for NETs
This trial tests whether it's safe to stop somatostatin analogues (SSAs) after PRRT (a type of radiation therapy for neuroendocrine tumors). It is for people with midgut, hindgut, or pancreatic NETs that have not responded to SSAs and now need PRRT.
Sydney, New South WalesAges 18 years+ - NCT05701241RecruitingPhase 4
Test continuing somatostatin shots after tumor progression in GEP NET
This trial studies whether it’s helpful to keep taking somatostatin “analog” injections even after your neuroendocrine tumor has started growing despite the usual dose. It also looks at how the next treatment choice (targeted pills or PRRT) fits in for people with non-functional, well-differentiated GEP NET.
Brasschaat, AntwerpAges 18 years+ - NCT06479811RecruitingPhase 1
Radioactive drug for advanced neuroendocrine and other cancers
This trial tests a new radioactive drug, [212Pb]VMT-Alpha-NET, that targets a protein on certain cancer cells. It is for people with specific types of advanced cancers that have gotten worse and are not responding to standard treatments.
Bethesda, MarylandAges 18–120 - NCT06830356Recruiting
PET-guided radiation for high-risk meningiomas
This trial uses a special PET scan to find active tumor areas and then delivers a stronger dose of radiation to those spots. It is for people with aggressive or returning meningiomas who have not had brain radiation before.
Aviano, PordenoneAges 16 years+ - NCT06855095RecruitingPhase 2/Phase 3
PRRT with long-acting hormone therapy for neuroendocrine tumors
This trial tests combining peptide receptor radionuclide therapy (PRRT) with long-acting somatostatin analogues to see how much radiation reaches the tumor. It is for people with neuroendocrine tumors who meet the standard criteria for PRRT.
AmsterdamAges 18 years+ - NCT07304466Recruiting
Terlipressin and somatostatin for portal pressure in liver transplant
This study tests two medicines (terlipressin and somatostatin) to see how they affect pressure in the portal vein during liver transplant. It may help people with high portal pressure who are getting a right lobe living donor liver transplant.
Istanbul, BagcilarAges 18–70 - NCT06427798RecruitingPhase 1/Phase 2
Radioactive drug for previously treated gut or adrenal tumors
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
Bethesda, MarylandAges 18–120 - NCT07605611Recruiting
Somatostatin and Diet vs. Stoma After Rectal Cancer Surgery
This trial tests whether using a medication called somatostatin plus a clear liquid diet can safely prevent serious complications after surgery to remove rectal cancer, without needing a temporary opening in the abdomen (stoma). You'll be randomly assigned to receive either somatostatin with diet changes or a stoma, depending on your individual risk factors.
Ezhou, HubeiAges 18–75 - NCT07150806RecruitingPhase 1/Phase 2
RYZ101 for progressive or recurrent meningioma
This trial is testing an investigational drug, RYZ101, for people with a type of brain tumor called meningioma that has grown back or not responded to other treatments. The goal is to see if RYZ101 can help stop the tumor from growing, and to check its safety. It might be an option if you have already had surgery or radiation.
Columbus, OhioAges 18 years+ - NCT06840821RecruitingPhase 1/Phase 2
Testing MB0151 for cancers with somatostatin receptors
This trial tests a new drug, MB0151, for adults with advanced solid tumors that have somatostatin receptors and have not responded to standard treatments. It aims to see if MB0151 is safe and can shrink tumors.
Jinan, ShandongAges 18 years+ - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Birmingham, AlabamaAges 18 years+ - NCT07413042RecruitingPhase 1
Radiation drug combined with immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy drug (Tislelizumab) as maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC) whose tumors have a specific protein (SSTR). If you have completed first-line treatment and your cancer shows SSTR on a PET scan, this study may be an option.
Beijing, Beijing MunicipalityAges 18–80 - NCT06611891RecruitingPhase 3
PET scan study for breast cancer with hormone receptors
This study tests a special PET scan called 68Ga-DOTATOC to see if it can find certain breast cancer cells in the body. It may help doctors better understand your cancer, especially if it has spread to the liver or bones.
GrenobleAges 18–99 - NCT06441331RecruitingPhase 1
Lu-177 edotreotide for children with SSTR-positive tumors
This trial tests a radioactive drug called Lu-177 edotreotide for children with a certain type of tumor (SSTR-positive) that hasn't responded to other treatments. The goal is to find the right dose and see how safe it is.
San Francisco, CaliforniaAges 2–18 - NCT03145857RecruitingPhase 1/Phase 2
Scan for certain tumors using a radioactive dotatate tracer
This early-phase study tests whether a special scan using 68Ga-HA-DOTATATE can help identify or diagnose tumors that have “somatostatin receptors.” It also checks how safe this scanning approach is and whether it provides useful information for people who may have these tumor types.
Edmonton, AlbertaAges 14 years+ - NCT04081701RecruitingPhase 4
Ga-68 DOTATATE PET/MRI for somatostatin-receptor brain tumors
This trial tests how well a special scan (Ga-68 DOTATATE PET combined with MRI) helps diagnose and guide treatment for certain brain tumors that have somatostatin receptors. It may help doctors better find tumor recurrence or remaining tumor after treatment.
New York, New YorkAges 18–100 - NCT04464122Recruiting
Testing blood markers to diagnose and gauge early response in NEN
This trial studies whether specific blood “biomarkers” can help confirm a type of cancer called NEN (neuroendocrine neoplasm) and show whether treatment is working early. It may help doctors start or adjust treatment sooner, especially for cancers that are advanced or have spread.
Rome, ItalyAges 18–80 - NCT04837885RecruitingPhase 2
Liver-targeted radioactive drug for GI or pancreas NET liver spread
This study tests a way to deliver a radioactive “somatostatin-type” medicine directly into the liver artery to treat liver-dominant spread of neuroendocrine tumors (NETs). It may help shrink or control liver metastases after standard treatment has not worked enough.
BordeauxAges 18 years+ - NCT04888481RecruitingPhase 2
Scan with a marker to find certain slow-growing tumors
This study tests an imaging scan using a special tracer (68Ga-HA-DOTATATE) to look for tumors that have somatostatin receptors. It may help doctors better locate suspected tumor sites so treatment planning can be more accurate.
Edmonton, AlbertaAges Any age - NCT04997317RecruitingPhase 1/Phase 2
Lu-177 targeting drug for returning or growing meningioma
This Phase 1/2 study tests a targeted radioactive medicine (Lu-177-satoreotide) for meningiomas that keep coming back or keep growing. It works only if tumor imaging shows the tumor has the right “target” signal, and it aims to see how well it can control the disease and how safe it is.
Basel, Canton of Basel-CityAges 18 years+ - NCT05636618RecruitingPhase 1/Phase 2
Targeted radiation for certain receptor-positive tumors
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
Jacksonville, FloridaAges 18–90 - NCT05918302RecruitingPhase 3
Compare radiotherapy versus everolimus for lung and thymus tumors
This study compares two treatment options for somatostatin receptor–positive neuroendocrine tumors from the lung or thymus: radiotherapy versus everolimus. It aims to see which treatment works better and how safe each option is for people whose disease has progressed within the last year.
Edegem, EdegemAges 18 years+ - NCT06416969RecruitingEarly Phase 1
Study of fat breakdown in overweight adults
This study looks at how fat cells in the belly release fat. Researchers want to learn more about fat breakdown in people who are overweight or obese. If you join, you may get a drug that helps them measure fat activity.
Rochester, MinnesotaAges 18–65 - NCT06597383Recruiting
Switching to pasireotide for acromegaly not well controlled
This trial tests if switching from a standard somatostatin analog to pasireotide can better control acromegaly in patients whose growth hormone and IGF-1 levels remain high. It aims to offer a more effective treatment option for those not responding well enough to initial therapy.
MilanAges 18 years+
What Somatostatin is being studied for
Conditions with recruiting Somatostatin studies.
Common questions
- Are there clinical trials studying Somatostatin?
- Yes. Clin2 currently lists 31 recruiting studies that include Somatostatin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Somatostatin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Somatostatin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Somatostatin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.